Core Viewpoint - The company, Betaini (300957.SZ), has signed a partnership agreement with Wuxi Jinyu Mao Medical Health Industry Investment Partnership (Limited Partnership), committing to invest 50 million yuan, which will give the company a 5% stake in the fund [1] Investment Details - The investment will be managed by Jinyu Mao Investment Management Co., Ltd. [1] - The partnership primarily focuses on sectors such as consumer healthcare, national health quality improvement (including wellness, medical aesthetics, special medical foods, and functional foods), pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI in pharmaceuticals [1]

Group 1: Macro Economic Insights - As of July 28, 32% of S&P 500 companies have reported Q2 earnings, with 77% exceeding expectations, up from 73% last year[1] - 62% of companies reported both revenue and net profit exceeding expectations, compared to 48% last year[1] - Q2 revenue growth rate was 5.0% year-on-year, while net profit growth rate was 5.5%, better than last year's 3.1% for non-financial companies[1] Group 2: Market Recommendations - It is suggested to buy on dips in the U.S. stock market, as historical trends show seasonal weakness from September to November[2] - The high yield of 10-year U.S. Treasury bonds may lead to a potential pullback in Q3, but a weaker dollar could enhance S&P 500 earnings[2] Group 3: Risks and Economic Data - Risks include trade negotiations falling short of expectations and escalating tariff conflicts[3] - U.S. existing home sales slightly declined to 3.93 million units in June, falling below the 4 million mark[8] - Initial jobless claims show a slow decline, while continuing claims remain high, indicating increased difficulty in the job market[8]